Sylogist (CVE:SYZ) received a C$17.00 price objective from research analysts at Acumen Capital in a research report issued on Wednesday. The firm currently has a “buy” rating on the stock. Acumen Capital’s price objective points to a potential upside of 25.93% from the stock’s previous close.
Separately, Cormark raised shares of Sylogist from a “buy” rating to a “top pick” rating and upped their target price for the stock from C$16.00 to C$18.00 in a report on Tuesday, September 18th.
Sylogist stock traded up C$0.10 on Wednesday, hitting C$13.50. The company’s stock had a trading volume of 5,944 shares, compared to its average volume of 15,074. Sylogist has a one year low of C$8.75 and a one year high of C$13.75.
In other Sylogist news, Director James Wilson bought 5,000 shares of the stock in a transaction that occurred on Tuesday, October 9th. The stock was acquired at an average cost of C$12.60 per share, with a total value of C$63,000.00. Also, insider David Elder bought 6,600 shares of the stock in a transaction that occurred on Tuesday, October 9th. The shares were acquired at an average cost of C$12.60 per share, with a total value of C$83,160.00. Over the last three months, insiders have purchased 13,300 shares of company stock valued at $167,715.
Sylogist Ltd., a technology innovation company, provides proprietary intellectual property solutions in Canada, the United States, the United Kingdom, and internationally. The company primarily offers proprietary enterprise application software and services for non-governmental organizations, non-profit organizations, and K-12 education markets.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for Sylogist Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sylogist and related companies with MarketBeat.com's FREE daily email newsletter.